These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 7985130)

  • 1. [The use of Cardioxan as a cardioprotective agent during antitumor chemotherapy].
    Lichinitser MR; Vyshinskaia GV; Min'kov ED; Nakhalova TA; Odzharova AA; Garin AM
    Ter Arkh; 1994; 66(7):54-6. PubMed ID: 7985130
    [No Abstract]   [Full Text] [Related]  

  • 2. [An evaluation of the cardioprotective action of the preparation ICRF-187 (Cardioxane) during the treatment of breast cancer with large doses of adriamycin].
    Min'kov ED; Niu-Tian-de GB; Shkhvatsabaia LV; Bagdasarov IuB; Zaĭtseva TI; Odzharova AA
    Ter Arkh; 1994; 66(10):64-6. PubMed ID: 7863453
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Cardioxan as a cardioprotector in antineoplastic chemotherapy].
    Lichinitser MP; Vyshinskaia GV; Min'kov ED; Nakhalova TA; Odzharova AA; Garin AM
    Klin Med (Mosk); 1996; 74(5):65-7. PubMed ID: 8999195
    [No Abstract]   [Full Text] [Related]  

  • 4. Amelioration of doxorubicin cardiotoxicity by the bispiperazinedione ICRF-187 in women with advanced breast cancer: a preliminary report.
    Jurga L; Misurová E; Vancík J
    Neoplasma; 1993; 40(4):259-62. PubMed ID: 8272153
    [No Abstract]   [Full Text] [Related]  

  • 5. Dexrazoxane cardioprotection for patients receiving FAC chemotherapy: a pharmacoeconomic evaluation.
    Tonkin K; Bates M; Lieu D; Arundell E; Williamson T; Zagari M
    Can J Oncol; 1996 Nov; 6(2):458-73. PubMed ID: 12056098
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A prospective randomized trial of ICRF-187 for prevention of cumulative doxorubicin-induced cardiac toxicity in women with breast cancer.
    Speyer JL; Green MD; Sanger J; Zeleniuch-Jacquotte A; Kramer E; Rey M; Wernz JC; Blum RH; Hochester H; Meyers M
    Cancer Treat Rev; 1990 Sep; 17(2-3):161-3. PubMed ID: 2125531
    [No Abstract]   [Full Text] [Related]  

  • 7. Doxorubicin-induced cardiomyopathy.
    Muggia FM; Speyer JL
    N Engl J Med; 1999 Feb; 340(8):654-5. PubMed ID: 10049088
    [No Abstract]   [Full Text] [Related]  

  • 8. [Prevention of cardiotoxicity of doxorubicin (Adriamycin) using cardioxane (ICRF-187, dexrazoxane) in the combination chemotherapy of disseminated breast cancer].
    Gershanovich ML; Moiceenko VM; Orlova RV
    Vopr Onkol; 1993; 39(1-3):26-32. PubMed ID: 8073671
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Doxorubicin-induced myocardial injury.
    Fujisaki G; Inokuchi C; Murashige N
    N Engl J Med; 2004 Oct; 351(18):1908-9; author reply 1908-9. PubMed ID: 15509827
    [No Abstract]   [Full Text] [Related]  

  • 10. [Adriamycin/cyclophosphamide: current standard in the adjuvant therapy of breast carcinoma? Or: how should one really put this question?].
    Cavalli F
    Schweiz Med Wochenschr; 1994 Oct; 124(43):1882-4. PubMed ID: 7973514
    [No Abstract]   [Full Text] [Related]  

  • 11. [Hemostimulating properties of cropanol during cytostatics-induced myelosuppression].
    Zhdanov VV; Gol'dberg VE; Khrichkova TIu; Matiash MG; Gur'iantseva LA; Simolina EI; Vysotskaia VV; Suslov NI; Popova NO; Dygaĭ AM
    Eksp Klin Farmakol; 2002; 65(6):37-40. PubMed ID: 12596531
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adult multicenter trials using dexrazoxane to protect against cardiac toxicity.
    Swain SM
    Semin Oncol; 1998 Aug; 25(4 Suppl 10):43-7. PubMed ID: 9768823
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Delayed administration of dexrazoxane provides cardioprotection against anthracyclines in breast cancer or acute myeloid leukemia.
    Lemez P
    J Clin Oncol; 1997 Oct; 15(10):3293-5. PubMed ID: 9336370
    [No Abstract]   [Full Text] [Related]  

  • 14. Cardioprotection with ICRF-187 (Cardioxane) in patients with advanced breast cancer having cardiac risk factors for doxorubicin cardiotoxicity, treated with the FDC regimen.
    Jelić S; Radulović S; Nesković-Konstantinović Z; Kreacić M; Ristović Z; Bosnjak S; Milanović N; Vuletić L
    Support Care Cancer; 1995 May; 3(3):176-82. PubMed ID: 7655778
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New drug counters doxorubicin cardiotoxicity; not for use at start of chemotherapy.
    Am J Health Syst Pharm; 1995 Oct; 52(19):2076. PubMed ID: 8535936
    [No Abstract]   [Full Text] [Related]  

  • 16. Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer.
    Swain SM; Whaley FS; Gerber MC; Weisberg S; York M; Spicer D; Jones SE; Wadler S; Desai A; Vogel C; Speyer J; Mittelman A; Reddy S; Pendergrass K; Velez-Garcia E; Ewer MS; Bianchine JR; Gams RA
    J Clin Oncol; 1997 Apr; 15(4):1318-32. PubMed ID: 9193323
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The use of Cardioxane in chemotherapy of malignant neoplasms in children].
    Safonova SA; Punanov IuA; Dedukh VM; Kolygin BA
    Vopr Onkol; 1997; 43(4):459-61. PubMed ID: 9381706
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Cardioxan--a drug of prevention of anthracycline-related cardiotoxicity in pediatric oncology].
    Kolygin BA
    Vopr Onkol; 2002; 48(1):110-2. PubMed ID: 12101558
    [No Abstract]   [Full Text] [Related]  

  • 19. Phase II clinical and pharmacological study of pirarubicin in combination with 5-fluorouracil and cyclophosphamide in metastatic breast cancer.
    Dhingra K; Frye D; Newman RA; Walters R; Theriault R; Fraschini G; Smith T; Buzdar A; Hortobagyi GN
    Clin Cancer Res; 1995 Jul; 1(7):691-7. PubMed ID: 9816034
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of dexrazoxane and other strategies to prevent cardiomyopathy associated with doxorubicin-taxane combinations.
    Sparano JA
    Semin Oncol; 1998 Aug; 25(4 Suppl 10):66-71. PubMed ID: 9768827
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.